Feed/Companies/GRIN Therapeutics

GRIN Therapeutics

As of 14 Oct 2026, GRIN Therapeutics has raised $140M across 1 verified round on record; latest: $140 million Series D+, announced 27 May 2025.

BUILT ON

Visit site

GRIN Therapeutics develops precision therapeutics targeting neurodevelopmental disorders resulting from NMDA receptor dysfunction, focusing primarily on pediatric patients.

grintherapeutics.comLinkedIn

LATEST ROUND

Series D+

$140M · 2025-05-27

RAISED ON RECORD · USD

$140M

across 1 verified round

INVESTORS

no lead named

SOURCES

from 1 publisher

Rounds

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series D+Series D financing

$140M · 2025-05-27

[ HISTORY ]

lead not stated

Round	Amount	Announced	Lead	Buzz
Series D+ Series D financing [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$140M	2025-05-27	not stated	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source

GRIN Therapeutics

Rounds

Company

Rounds

Sources

Profile

Investors

GRIN Therapeutics

Rounds

Profile

Sources

Series D+$140M2025-05-271 source

Investors

Series D+$140M2025-05-272 investors